BioMarin Pharmaceutical

American company

BMRN Nasdaq ISIN US09061G1013 SEC CIK 1048477 LEI NSLL8ITTRR0J5HEMR848
Follow BioMarin Pharmaceutical Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $1B +32% vs same quarter last year
Net income −$122.8M −299.5% vs same quarter last year
EPS, diluted −$0.63 −293.8% vs same quarter last year
Operating cash flow $188.2M −48.9% vs same quarter last year
Revenue by quarter
$747.3M
$745.1M
$825.4M
$776.1M
$874.6M
$766.2M
$989.7M
$1B
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$1B$0$1B$2B$3B$4BFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$3.2B$348.9M
FY24$2.9B$426.9M
FY23$2.4B$167.6M
FY22$2.1B$141.6M
FY21$1.8B−$64.1M
FY20$1.9B$854M
FY19$1.7B−$23.8M
FY18$1.5B−$77.2M
FY17$1.3B−$117M
FY16$1.1B−$630.2M
FY15$889.9M−$171.8M
FY14$749.3M−$134M
FY13$548.5M−$176.4M
FY12$500.7M−$114.3M
FY11$441.4M−$53.8M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−100%−50%0%50%100%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2577.7%12.7%10.8%
FY2479.7%17%15%
FY2378%7.7%6.9%
FY2276%7.7%6.8%
FY2174.5%−4.5%−3.5%
FY2071.8%−2.3%45.9%
FY1978.9%−5.9%−1.4%
FY1878.9%−8.3%−5.2%
FY1781.6%−1.1%−8.9%
FY1681.2%−71.9%−56.4%
FY1582.9%−12.4%−19.3%
FY1483.7%−12.4%−17.9%
FY1383.9%−28.4%−32.2%
FY1281.7%−22%−22.8%
FY1181%−7.7%−12.2%
Free cash flowOperating cash flow minus capital expenditure
−$500M$0$500M$1BFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25$725M
FY24$487.4M
FY23$62.6M
FY22$54.9M
FY21$209M
FY20−$28.9M
FY19−$96.8M
FY18−$124.4M
FY17−$208M
FY16−$376.2M
FY15−$447.2M
FY14−$187.5M
FY13−$124.8M
FY12−$27M
FY11−$54.8M
Returned to shareholdersDividends paid and shares bought back
$0$20M$40M$60MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearBuybacks
FY25-
FY24-
FY23-
FY22$0
FY21$0
FY20$50M
FY19$0
FY18$0
FY17-
FY16-
FY15-
FY14-
FY13-
FY12-
FY11-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • BioMarin Pharmaceutical
  • Healthcare median
−100%−50%0%50%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearBioMarin PharmaceuticalHealthcare median
FY2510.8%−30.6%
FY2415%−47%
FY236.9%−58%
FY226.8%−80.4%
FY21−3.5%−71.9%
FY2045.9%−62.2%
FY19−1.4%−46.3%
FY18−5.2%−49.6%
FY17−8.9%−45.9%
FY16−56.4%−36%
FY15−19.3%−38.4%
FY14−17.9%−35.5%
FY13−32.2%−37.1%
FY12−22.8%−29.1%
FY11−12.2%−27.9%